Eledon Announces Presentation of Updated Data from Investigator-Initiated Islet Transplant Trial of Tegoprubart in Patients with Type 1 Diabetes at American Diabetes Association (ADA) 2026 Scientific Sessions
Eledon Pharmaceuticals will present updated results from an investigator-initiated islet transplant trial of its lead asset, tegoprubart, at the American Diabetes Association 2026 Scientific Sessions. The oral presentation, titled 'Anti-CD40L to Induce Graft Survival and Function in Islet Allotransplantation,' will be delivered by Dr. Piotr Witkowski of the University of Chicago Medicine Transplant Institute on June 7, 2026.
Key figures
- Drug Name
- tegoprubart
- Conference
- American Diabetes Association 86th Scientific Sessions
- Presentation date
- June 7, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.